Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $145.00

Merck & Co., Inc. (NYSE:MRK) had its target price raised by Cantor Fitzgerald from $120.00 to $145.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other research analysts have also recently commented on the stock. Jefferies Financial Group raised their target price on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. BMO Capital Markets increased their price target on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, August 20th. Argus lifted their price objective on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Finally, Bank of America upped their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Seventeen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $151.32.

Merck & Co., Inc. Trading Up 2.2%

Shares of Merck & Co., Inc. stock opened at $145.52 on Thursday. The firm has a 50-day moving average of $143.90 and a 200-day moving average of $128.28. The stock has a market cap of $359.03 billion, a PE ratio of 116.42, a PEG ratio of 6.55 and a beta of 0.21. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the prior year, the company posted $2.13 earnings per share. Merck & Co., Inc.’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were paid a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP David Williams sold 52,847 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last three months. Insiders own 0.17% of the company’s stock.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of hedge funds have recently made changes to their positions in the stock. Susquehanna Fundamental Investments LLC purchased a new position in Merck & Co., Inc. in the 2nd quarter worth $11,470,000. Russell Investments Group Ltd. lifted its stake in Merck & Co., Inc. by 2.0% in the second quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock worth $331,931,000 after purchasing an additional 51,393 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Merck & Co., Inc. by 7.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company’s stock valued at $794,577,000 after buying an additional 402,011 shares during the period. Talon Private Wealth LLC purchased a new stake in Merck & Co., Inc. during the second quarter valued at about $995,000. Finally, Panagora Asset Management Inc. grew its stake in shares of Merck & Co., Inc. by 410.5% during the fourth quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock valued at $74,255,000 after buying an additional 567,249 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck is participating in a broad rally across biotechnology and vaccine stocks, providing sector-wide momentum for MRK shares. Novavax Soars, Moderna Surges, Merck Climbs as Biotech Rallies
• Positive Sentiment: The FDA approved Merck’s WELIREG plus LENVIMA combination for adults with advanced kidney cancer previously treated with PD-1 or PD-L1 therapies. The approval expands Merck’s oncology opportunity beyond its core Keytruda franchise. Merck also started a Phase I trial involving Cyprumed’s oral peptide-delivery platform, adding a potential pipeline catalyst. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while Morgan Stanley maintained or issued a Buy view in separate coverage. These actions suggest some analysts see the recent weakness and long-term growth prospects as attractive. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, although the position is too small to materially affect Merck’s fundamentals. Apella Capital Increases Stake in Merck
• Negative Sentiment: A Dutch court blocked Merck’s planned subcutaneous Keytruda product in eight European markets amid a patent dispute with Halozyme. The ruling could delay a potentially important reformulation and complicate efforts to extend Keytruda’s commercial life. HALO Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Merck is viewed as one of the pharmaceutical companies most exposed to upcoming patent losses and generic competition, raising longer-term concerns about revenue after Keytruda’s exclusivity period. Analysts have also flagged mixed growth prospects, while Morgan Stanley issued a separate pessimistic forecast. Pharma’s $500 Billion Patent Problem Will Come in Waves

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.